APGE•benzinga•
Apogee Therapeutics Says Cash, Cash Equivalents And Marketable Securities Of $731.1M As Of December 31, 2024 Is Expected To Provide Cash Runway Into Q1 2028
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 3, 2025 by benzinga